Epstein-Barr Virus: Implicated in Cancer Etiology in China, Impetus for a Vaccine

Virologist Hans Wolf of the University of Regensburg in Germany has been working on the etiology of nasopharyngeal carcinoma (NPC) in areas of China since 1979. Researchers from the U.S. National Cancer Institute (NCI), too, have been working with their Chinese colleagues on cancer epidemiology and etiology. The reasons for this cooperative research vary, but as Federico Welsch, associate director for international affairs at NCI, points out, "They have some cancers that are rare in the develop

Written byMyrna Watanabe
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

Virologist Hans Wolf of the University of Regensburg in Germany has been working on the etiology of nasopharyngeal carcinoma (NPC) in areas of China since 1979. Researchers from the U.S. National Cancer Institute (NCI), too, have been working with their Chinese colleagues on cancer epidemiology and etiology. The reasons for this cooperative research vary, but as Federico Welsch, associate director for international affairs at NCI, points out, "They have some cancers that are rare in the developed world." Among these are nasopharyngeal cancer, certain liver cancers, and esophageal cancer. Environmental factors have been implicated.

Research by Wolf and Chinese colleagues Yi Zeng, chief of the department of tumor viruses at the Institute of Virology, Chinese Academy of Preventive Medicine (CAPM) and former president of CAPM, Shu-Yan Gu, now deputy director of the National Center for AIDS Prevention and Control, and others, is leading to development of a vaccine.

In work ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies